@the_news_21
The Covid-19 situation in India is heartbreaking as many patients are struggling to get oxygen and life saving drugs. So to help drug firm Gilead Sciences on Tuesday said it is taking several steps to expand the availability of antiviral drug Remdesivir in India. It will also be donating a minimum of 4.5 lakh vials of ‘Veklury’ to the Indian government.
“In response to the rapid increase in COVID-19 cases in India, the company is providing its voluntary licensing partners with technical assistance, support for the addition of new local manufacturing facilities and the donation of active pharmaceutical ingredient (API) to rapidly scale up production of Remdesivir”, Gilead Sciences Inc said in a statement.
All seven of Gilead’s licensees based in India–Cipla, Dr Reddy”s Laboratories, Hetero Labs, Jubilant Lifesciences, Mylan, Syngene and Zydus Cadila Healthcare–have significantly accelerated production of Remdesivir by scaling up their batch sizes, adding new manufacturing facilities and/or onboarding local contract manufacturers across the country, Gilead Sciences said on Monday.